Apalutamide and Topiramate Capsules
Determining the interaction of Apalutamide and Topiramate Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes. MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy. References "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.
MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy.
- "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: topiramate
Brand name: Qudexy XR Sprinkle, Topamax, Topamax Sprinkle, Trokendi XR, Topiragen, Qudexy XR
Synonyms: Topiramate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Apalutamide-Topiramate ER Capsules
- Apalutamide-Topiramate Extended-Release Capsules
- Apalutamide-Topiramate Extended-Release Sprinkle Capsules
- Apalutamide-Topiramate Sprinkle Capsules
- Apalutamide-Topiramate Tablets
- Apalutamide-Topisulf Cream
- Topiramate Capsules-APAP w/Codeine
- Topiramate Capsules-Apetex
- Topiramate Capsules-Apetigen
- Topiramate Capsules-Apetigen-Plus
- Topiramate Capsules-ApexiCon
- Topiramate Capsules-ApexiCon E